Company / R&D per Share
NewAmsterdam Pharma Co N.V. R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.91
FY2025
5-year range
$2.64 / $4.57
FY2021-FY2025
Trend
-6.3%
vs FY2024
Sector context
#53 of 208
Health Care
What the data says
NewAmsterdam Pharma Co N.V.'s r&d per share of $3.91 is higher than 75% of companies in the Health Care sector (FY2025). R&D per Share has declined for 3 consecutive years, from $4.57 in FY2022 to $3.91 in FY2025.
Based on SEC 10-K filings.
3.91 in FY2025 with a 3-year CAGR of -5.1%.
Declined from $4.40 to $3.91 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -5.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 208This company $3.91 Sector average $28.82
▼
-86.4% below sector average
Key checks
Key Insights
- NewAmsterdam Pharma Co N.V.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 6.3% year-over-year.
- Ranks #53 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.91 | -6.3% |
| FY2024 | $4.18 | -5.0% |
| FY2023 | $4.40 | -3.9% |
| FY2022 | $4.57 | +73.3% |
| FY2021 | $2.64 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026